Researchers published data showing an ultrasensitive immunoassay detected a 50.5-fold surge in eMTBR-tau at Braak stage VI versus stages I-II across two autopsy cohorts.
Blood tests for Alzheimer’s disease reached a new milestone on November 16 when researchers published data on an ultrasensitive immunoassay capable of identifying advanced tau tangles in the brain, Medscape reported.
Plasma phosphorylated tau 217 effectively spots soluble tau pathology tied to amyloid plaques. Yet, that marker struggles to track insoluble tau tangles that drive actual neurodegeneration and cognitive decline.
Scientists developed a high-sensitivity immunoassay targeting endogenously cleaved microtubule-binding region tau, known as eMTBR-tau243. While previous testing required complex mass spectrometry available in only a few specialized laboratories, this new test uses just 35 microliters of plasma.
Brain Donors and Imaging Cohorts
Researchers evaluated the immunoassay using blood samples collected before death from 521 brain donors across two US autopsy cohorts. They also tested 207 participants from two tau PET imaging cohorts, according to findings published in JAMA.
Concentrations of plasma eMTBR-tau increased markedly as neurofibrillary tangle pathology advanced into the neocortex during Braak stages V and VI. At Braak stage VI, eMTBR-tau levels surged 50.5-fold and 25.2-fold higher than stages I-II across the two autopsy cohorts.
By comparison, increases for p-tau217 remained much smaller at 4.6-fold and 3.2-fold in those same cohorts. In one autopsy cohort, eMTBR-tau achieved an area under the curve of 0.93 for distinguishing advanced stages from earlier ones, compared with 0.84 for p-tau217.
Data from the tau-PET imaging cohorts matched the autopsy results. In the 99-participant TRIAD cohort, eMTBR-tau concentrations rose nearly 60-fold at tau-PET Braak stages V-VI compared with stage 0, while p-tau217 increased 4.9-fold.
Nicholas Ashton, PhD, senior director of Banner’s Fluid Biomarker Program at Banner Sun Health Research Institute in Sun City, Arizona, presented the study at the 19th Clinical Trials on Alzheimer’s Disease Conference.
“I still think we’re missing that sensitivity, or maybe missing that novel biomarker for the earlier [Braak] stage regions,” Ashton said, noting that the test specifically detects late-stage tau.
Tatiana Marcal, MD, senior director of medical affairs and clinical programs at the Alzheimer’s Association, discussed how the new test might fit into current diagnostic pipelines. She spoke to Medscape Medical News about combining markers.
“P-tau217 and eMTBR-tau are likely complementary, and there may eventually be a series or panel that could measure and help with staging of someone’s underlying biology,” Marcal told Medscape Medical News.
Investigators pointed out several study limitations, including a cross-sectional design, small imaging cohorts, and limited racial and ethnic diversity. Many eMTBR-tau values at early Braak stages also fell below the assay limit of quantification.
Larger prospective studies must now establish clinical cutoffs and determine if the test accurately predicts cognitive decline or treatment response. Ashton said that the small blood volume required could eventually support decentralized research and remote collection once validated.
Common Questions About the Tau Immunoassay
How much blood does the new eMTBR-tau test require?
The high-sensitivity immunoassay requires just 35 microliters of plasma. Older mass spectrometry methods required 1.5 milliliters.
How did eMTBR-tau perform against p-tau217 in autopsy samples?
At Braak stage VI, eMTBR-tau levels were up to 50.5-fold higher than stages I-II, whereas p-tau217 increases reached a maximum of 4.6-fold across the same cohorts.
What are the next steps for validating the immunoassay?
Researchers must conduct larger prospective studies to establish clinical cutoffs, test performance across different laboratories, and evaluate whether the assay predicts patient responses to Alzheimer’s treatments.